Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-07-28Clinical Trial Update: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 4]
Phase 4 trial comparing ixekizumab to guselkumab in moderate-to-severe plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-07-28Clinical Trial Update: Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial update assessing efficacy, safety, and immunogenicity of AVT02 in moderate-to-severe chronic plaque psoriasis.
-
FDA approval · 2020-07-20FDA Approved: WYNZORA — Original Application (MC2 Therapeutics Ltd)
FDA approved Wynzora, a fixed-dose combination of calcipotriene and betamethasone dipropionate, under an original NDA by MC2 Therapeutics Lt…
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…
-
CLINICAL_TRIALS trial_result · 2020-06-18Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]
A Phase 2 clinical trial of mirikizumab (LY3074828) in adults with moderate to severe plaque psoriasis has completed, with results posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-06-16FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2020-05-29FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under…
-
FDA approval · 2020-05-11FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved Cosette Pharmaceuticals' generic Calcipotriene and Betamethone Dipropionate combination for the treatment of plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2020-04-15Clinical Trial Update: ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. [Phase 4]
Phase 4 trial update evaluating ILUMYA in combination with HALOG Ointment 0.1% for plaque psoriasis; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis [Phase 1]
Phase 1 first-in-human study evaluating safety, tolerability, and pharmacology of PF-06826647 in healthy subjects and patients with plaque p…
-
CLINICAL_TRIALS trial_result · 2020-03-30Clinical Trial Update: A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis [Phase 2]
A Phase 2 clinical trial of PRCL-02 in moderate to severe chronic plaque psoriasis has completed with results posted.
-
FDA approval · 2020-03-26FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TALTZ (ixekizumab) from Eli Lilly and Company, indicating an updated or expanded indication …
-
CLINICAL_TRIALS trial_result · 2020-03-17Clinical Trial Update: Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 study of ixekizumab in children aged 6 to under 18 with moderate-to-severe plaque psoriasis completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients [Phase 4]
Phase 4 trial assessing secukinumab versus placebo on fat tissue and skin in plaque psoriasis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis [Phase 3]
Phase 3 trial comparing 188-0551 spray to vehicle spray in plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307) [Phase 3]
A Phase 3 clinical trial comparing 188-0551 spray to a vehicle spray in subjects with plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis [Phase 4]
This Phase 4 trial compared subcutaneous brodalumab to oral dimethyl fumarate for adults with moderate to severe plaque psoriasis, and resul…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis [Phase 3]
Phase 3 long-term safety study of IDP-118 lotion for plaque psoriasis completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis [Phase 3]
Phase 3 trial update on IDP-122 for plaque psoriasis reports completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis [Phase 3]
Phase 3 trial updating safety and efficacy of IDP-122 for plaque psoriasis; study completed with results posted.
-
FDA approval · 2020-01-27FDA Approved: CLOBETASOL PROPIONATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's generic clobetasol propionate topical product under an original application, expanding access…
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 study of brodalumab in moderate to severe plaque psoriasis has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects [Phase 3]
Phase 3 trial update on efficacy, safety, withdrawal, and retreatment with brodalumab in moderate to severe plaque psoriasis; study terminat…
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects [Phase 3]
Phase 3 trial evaluating efficacy and safety of brodalumab versus placebo and ustekinumab in moderate-to-severe plaque psoriasis has been te…
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 3]
Phase 3 trial update on secukinumab for moderate-to-severe chronic plaque-type psoriasis; results posted after completion.